Continue to site >
Trending ETFs
You have successfully subscribed to Advisor Access. Thank you!
Help us personalize your experience.
Which type of investor describes you best?
Help us personalize your experience.
What is your AUM?
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.

Congratulations on personalizing your experience.

Email is verified. Thank you!

Name

As of 06/01/2026

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Horizon Kinetics Medical ETF

MEDX | Active ETF

$33.60

$17.8 M

1.22%

$0.41

0.85%

Vitals

YTD Return

1.2%

1 yr return

30.1%

3 Yr Avg Return

5.9%

5 Yr Avg Return

N/A

Net Assets

$17.8 M

Holdings in Top 10

71.3%

52 WEEK LOW AND HIGH

$34.3
$26.38
$35.45

Expenses

OPERATING FEES

Expense Ratio 0.85%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover N/A

Redemption Fee N/A

Min Investment

Standard (Taxable)

N/A

IRA

N/A

Fund Classification

Fund Type

Exchange Traded Fund

Name

As of 06/01/2026

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Horizon Kinetics Medical ETF

MEDX | Active ETF

$33.60

$17.8 M

1.22%

$0.41

0.85%

MEDX - Profile

Distributions

  • YTD Total Return 1.2%
  • 3 Yr Annualized Total Return 5.9%
  • 5 Yr Annualized Total Return N/A
  • Capital Gain Distribution Frequency N/A
  • Net Income Ratio N/A
DIVIDENDS
  • Dividend Yield 1.2%
  • Dividend Distribution Frequency Annual

Fund Details

  • Legal Name
    Horizon Kinetics Medical ETF
  • Fund Family Name
    N/A
  • Inception Date
    Sep 30, 1999
  • Shares Outstanding
    N/A
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    US

Fund Description

span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:540pt"The Fund is an actively managed exchange-traded fund (“ETF”) that pursues its investment objective by investing, under normal/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:576pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /spandiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:457.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.83pt"circumstances, at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities,/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.83pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:469.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.88pt"warrants and other equity securities having the characteristics of common stocks (such as American Depositary Receipts (“ADRs”),/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.88pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:481.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.88pt"Global Depositary Receipts (“GDRs”) and International Depositary Receipts (“IDRs”)) of U.S. and foreign companies engaged in/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.88pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:493.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.97pt"medical research, pharmaceutical and medical technology industries and related technology industries, generally, with an emphasis/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.97pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:505.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.96pt"toward companies engaged in cancer research and drug development, such as pharmaceutical development companies, surgical and/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.96pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:517.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:540pt"medical instrument manufacturers and developers, pharmaceutical manufacturers, and biotech and medical research companies. These/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:576pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:529.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.86pt"types of companies derive at least 50% of their revenue from such activities. The Fund also may invest in other ETFs and purchase/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.86pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:541.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:258.61pt"and write options for hedging purposes and/or direct investment./spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:294.61pt;position:var(--position);text-decoration:none;white-space:pre;width:281.21pt" In addition, the Fund may purchase or engage in short sales of certain/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.82pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:553.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:107.65pt"leveraged or inverse ETFs./span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:571.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.89pt"The Fund may invest up to 20% of its total assets in convertible and non-convertible debt securities rated below investment grade, also/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.89pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:583.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.99pt"known as junk bonds, or unrated securities that Horizon Kinetics Asset Management LLC, the Fund’s investment adviser (the/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.99pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:595.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:224.44pt"“Adviser”), has determined to be of comparable quality./spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:260.44pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:613.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.92pt"The Adviser selects portfolio securities by evaluating a company’s positioning and the resources that it currently expends on research/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.92pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:625.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.94pt"and development, looking for a significant percentage, or large amount, of capital invested into research and treatment of cancer and/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.94pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:637.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.94pt"other diseases. The Adviser also considers a company’s fundamentals by reviewing its balance sheets, corporate revenues, earnings/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.94pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:649.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.99pt"and dividends. The Adviser also considers at the amount of capital a company spends on research and development because the/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.99pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:661.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.89pt"Adviser believes that such expenditures frequently have significant bearing on future growth. The Fund may invest in companies of/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.89pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:673.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.89pt"any size, including small and medium-size companies. Additionally, the Fund may participate in securities lending arrangements up to/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.89pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:685.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.97pt"33 1/3% of the securities in its portfolio with brokers, dealers, and financial institutions (but not individuals) to seek to increase the/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.97pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:697.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:88.26pt"return on its portfolio./span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:715.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.83pt"Decisions to sell the Fund’s portfolio holdings are generally triggered by either adequate value being achieved, as determined by the/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.83pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:727.5pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.84pt"Adviser, or an adverse change in a company’s operating performance or a deterioration of the company’s business model. A sell/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.84pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:36pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.86pt"trigger also may occur if the Adviser discovers a new investment opportunity that it believes is more compelling and represents a/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.86pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:48pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:276.65pt"greater risk reward profile than other investment(s) held by the Fund./span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:66pt;width:612pt"divspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.95pt"The Fund may maintain during a temporary period of abnormal conditions, a significant portion of its total assets in cash and/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.95pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/div/divdivdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:78pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.86pt"securities, generally considered to be cash and cash equivalents, including, but not limited to: high quality, U.S. short-term debt/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.86pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:90pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:540pt"securities and money market instruments. The Adviser will invest in such short-term cash positions to the extent the Adviser is unable/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:576pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:102pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.91pt"to find sufficient investments meeting its criteria and when the Adviser believes the purchase of additional equity securities would not/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.91pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:114pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.92pt"further the investment objective of the Fund during such periods of time. Additionally, to respond to adverse market, economic,/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.92pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:126pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.84pt"political or other conditions, which may persist for short or long periods of time, the Fund may invest up to 100% of its assets in the/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.84pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/div/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:138pt;width:612pt"divspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:404.86pt"types of high quality, U.S. short-term debt securities and money market instruments described above./span/divspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:440.86pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:156pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.97pt"If the market advances during periods when the Fund is holding a large cash position, the Fund may not participate in the positive/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.97pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:168pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.93pt"performance as much as it would have if it had been more fully invested in securities. During the temporary periods mentioned in the/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.93pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:180pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.89pt"paragraph above, the Adviser believes that an additional amount of liquidity in the Fund is desirable both to meet operating/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.89pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:192pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.83pt"requirements and to take advantage of new investment opportunities. When the Fund holds a significant portion of assets in cash and/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.83pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:204pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:233.01pt"cash equivalents, it may not meet its investment objective./spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:269.01pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:222pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:174.02pt"The Fund will concentrate its investments (/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:italic;font-weight:normal;left:210.02pt;position:var(--position);text-decoration:none;white-space:pre;width:12.2pt"i.e./spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:222.22pt;position:var(--position);text-decoration:none;white-space:pre;width:172.73pt", hold more than 25% of its total assets) in /spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:394.95pt;position:var(--position);text-decoration:none;white-space:pre;width:181.05pt"companies engaged in the Medical Research,/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:576pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:234pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:539.96pt"Pharmaceutical and Technology Industries and related medical technology industries, generally, with an emphasis toward companies/spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:575.96pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divdiv style="font-size:12pt;line-height:10pt;position:var(--position);text-align:justify;text-align-last:var(--justify);top:246pt;width:612pt"span style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:202.24pt"engaged in cancer research and drug development./spanspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:238.24pt;position:var(--position);text-decoration:none;white-space:pre;width:2.5pt" /span/divspan style="font-family:'Times New Roman', serif;font-size:10pt;font-style:normal;font-weight:normal;left:36pt;position:var(--position);text-decoration:none;white-space:pre;width:514.18pt"The Fund is classified as a “non-diversified” investment company under the Investment Company Act of 1940 (the “1940 Act”)./span
Read More

MEDX - Performance

Return Ranking - Trailing

Period MEDX Return Category Return Low Category Return High Rank in Category (%)
YTD 1.2% N/A N/A N/A
1 Yr 30.1% N/A N/A N/A
3 Yr 5.9%* N/A N/A N/A
5 Yr N/A* N/A N/A N/A
10 Yr N/A* N/A N/A N/A

* Annualized

Return Ranking - Calendar

Period MEDX Return Category Return Low Category Return High Rank in Category (%)
2025 27.1% N/A N/A N/A
2024 -6.4% N/A N/A N/A
2023 N/A N/A N/A N/A
2022 N/A N/A N/A N/A
2021 N/A N/A N/A N/A

Total Return Ranking - Trailing

Period MEDX Return Category Return Low Category Return High Rank in Category (%)
YTD 1.2% N/A N/A N/A
1 Yr 30.1% N/A N/A N/A
3 Yr 5.9%* N/A N/A N/A
5 Yr N/A* N/A N/A N/A
10 Yr N/A* N/A N/A N/A

* Annualized

Total Return Ranking - Calendar

Period MEDX Return Category Return Low Category Return High Rank in Category (%)
2025 28.6% N/A N/A N/A
2024 -4.7% N/A N/A N/A
2023 N/A N/A N/A N/A
2022 N/A N/A N/A N/A
2021 N/A N/A N/A N/A

MEDX - Holdings

Concentration Analysis

MEDX Category Low Category High MEDX % Rank
Net Assets 17.8 M N/A N/A N/A
Number of Holdings 33 N/A N/A N/A
Net Assets in Top 10 12.9 M N/A N/A N/A
Weighting of Top 10 71.26% N/A N/A N/A

Top 10 Holdings

  1. Eli Lilly Co 15.59%
  2. US BANK MMDA - USBGFS 7 10.03%
  3. AbbVie Inc 8.43%
  4. Novartis AG 7.40%
  5. Johnson Johnson 5.93%
  6. AstraZeneca PLC 5.71%
  7. Bristol-Myers Squibb Co 5.13%
  8. Ionis Pharmaceuticals Inc 4.73%
  9. Amgen Inc 4.19%
  10. Alnylam Pharmaceuticals Inc 4.14%

Asset Allocation

Weighting Return Low Return High MEDX % Rank
Stocks 		92.06% N/A N/A N/A
Cash 		10.03% N/A N/A N/A
Preferred Stocks 		0.00% N/A N/A N/A
Other 		0.00% N/A N/A N/A
Convertible Bonds 		0.00% N/A N/A N/A
Bonds 		0.00% N/A N/A N/A

Stock Sector Breakdown

Weighting Return Low Return High MEDX % Rank
Utilities 		0.00% N/A N/A N/A
Technology 		0.00% N/A N/A N/A
Real Estate 		0.00% N/A N/A N/A
Industrials 		0.00% N/A N/A N/A
Healthcare 		0.00% N/A N/A N/A
Financial Services 		0.00% N/A N/A N/A
Energy 		0.00% N/A N/A N/A
Communication Services 		0.00% N/A N/A N/A
Consumer Defense 		0.00% N/A N/A N/A
Consumer Cyclical 		0.00% N/A N/A N/A
Basic Materials 		0.00% N/A N/A N/A

Stock Geographic Breakdown

Weighting Return Low Return High MEDX % Rank
US 		92.06% N/A N/A N/A
Non US 		0.00% N/A N/A N/A

MEDX - Expenses

Operational Fees

MEDX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.85% N/A N/A N/A
Management Fee 0.85% N/A N/A N/A
12b-1 Fee N/A N/A N/A N/A
Administrative Fee N/A N/A N/A N/A

Sales Fees

MEDX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A N/A N/A N/A
Deferred Load N/A N/A N/A N/A

Trading Fees

MEDX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A N/A N/A N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

MEDX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover N/A N/A N/A N/A

MEDX - Distributions

Dividend Yield Analysis

MEDX Category Low Category High MEDX % Rank
Dividend Yield 1.22% N/A N/A N/A

Dividend Distribution Analysis

MEDX Category Low Category High Category Mod
Dividend Distribution Frequency Annual

Net Income Ratio Analysis

MEDX Category Low Category High MEDX % Rank
Net Income Ratio N/A N/A N/A N/A

Capital Gain Distribution Analysis

MEDX Category Low Category High Capital Mode
Capital Gain Distribution Frequency

Distributions History

View More +

MEDX - Fund Manager Analysis

Tenure Analysis

Category Low Category High Category Average Category Mode
N/A N/A N/A N/A

Advertisement

×

Wait! Do you know all the important aspects of mutual funds?

×

Free Advisor Access newsletter emailed to you.

Receive free and exclusive email updates for financial advisors about best performers, news, CE accredited webcasts and more.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.